BioNTech (NASDAQ:BNTX) Raised to “Buy” at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX) from a neutral rating to a buy rating in a research note published on Friday, MarketBeat Ratings reports. The brokerage currently has $137.00 target price on the stock, up from their previous target price of $90.00.

A number of other research analysts have also recently commented on the stock. Morgan Stanley raised shares of BioNTech from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $93.00 to $145.00 in a research report on Tuesday, September 24th. JPMorgan Chase & Co. reduced their price target on shares of BioNTech from $125.00 to $124.00 and set a “neutral” rating on the stock in a research report on Monday, November 4th. Deutsche Bank Aktiengesellschaft increased their price target on shares of BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, September 19th. Jefferies Financial Group raised shares of BioNTech from a “hold” rating to a “buy” rating and increased their price target for the stock from $96.00 to $150.00 in a research report on Tuesday, September 17th. Finally, UBS Group increased their price target on shares of BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 18th. Four research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $137.54.

BioNTech Trading Down 1.7 %

Shares of BNTX opened at $108.73 on Friday. The company has a current ratio of 7.33, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49. The firm has a 50-day moving average price of $112.26 and a 200 day moving average price of $96.82. The firm has a market capitalization of $25.85 billion, a P/E ratio of -51.78 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. During the same quarter in the prior year, the firm posted $0.73 earnings per share. BioNTech’s quarterly revenue was up 38.9% on a year-over-year basis. Sell-side analysts forecast that BioNTech will post -3.47 EPS for the current year.

Hedge Funds Weigh In On BioNTech

Hedge funds have recently modified their holdings of the business. Covestor Ltd grew its position in shares of BioNTech by 47.2% during the first quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after acquiring an additional 133 shares during the last quarter. GAMMA Investing LLC lifted its holdings in BioNTech by 86.9% in the second quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock valued at $41,000 after acquiring an additional 238 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in BioNTech by 106.3% in the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after acquiring an additional 252 shares during the period. Planning Capital Management Corp raised its stake in shares of BioNTech by 45,000.0% during the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after buying an additional 450 shares during the last quarter. Finally, Blue Trust Inc. raised its stake in shares of BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after buying an additional 388 shares during the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.